Market News
Recent Developments
Agreements
- On October 03, 2023, Sanofi, a global pharmaceutical company announced that it has entered into an agreement with Janssen Global Services, LLC, a global pharmaceutical company to develop and commercialize the vaccine candidate for extraintestinal pathogenic E. coli
Key Strategic Initiatives
- In March 2021, Xiamen Innovax Biotech Co., Ltd, a China based biopharmaceutical company initiated a study Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli) for the treatment of conditions such as Cervical Intraepithelial Neoplasia. The study is expected to be completed in January, 2024.
Figure 2. Global Escherichia Coli Strain Market Share (%), By Strain Type, 2023